Ikena Oncology, Inc. SEC filings document the former IKNA oncology issuer, its clinical-development disclosures, and its later corporate transition under the name neBio, Inc. The filings include material-event reports, material agreements, shareholder voting matters, capital-structure disclosures, operating and financial results, and risk and clinical-regulatory updates.
Recent Form 8-K disclosures also record governance and reporting matters, including an independent auditor change, equity inducement plan disclosures, compensation-plan documentation, and registered common stock identified under the IMA symbol on The Nasdaq Capital Market.
Schedule 13D/A (Am. No. 5) — ImageneBio, Inc.
OrbiMed Advisors LLC and affiliated funds updated their stake following the 25 Jul 2025 1-for-12 reverse split and PIPE financing tied to the Ikena-Inmagene merger. Outstanding shares rose to 11,181,676, cutting the group’s ownership by >1 ppt to 773,754 shares (6.92%).
Break-down: OrbiMed Private Investments VI, LP holds 753,063 shares (6.73%); Worldwide Healthcare Trust PLC, advised by OrbiMed Capital LLC, owns 135,516 shares (1.21%); OrbiMed Genesis Master Fund, LP holds 20,691 shares (0.19%). Voting/dispositive power is largely shared among OrbiMed Advisors, OrbiMed Capital GP VI LLC, and OrbiMed Genesis GP LLC.
On 25 Jul 2025 OPI VI bought 83,611 PIPE shares at $2.49 each (≈$29.90 post-split); cash came from partnership working capital. The investors secured demand, piggy-back and Form S-3 registration rights; Director David P. Bonita’s equity awards are assigned to OrbiMed. The group states no present plans for further corporate actions but may trade shares opportunistically.